Chinese vaccine specialist CanSino Biologics Inc received Beijing’s patent approval for its Covid-19 Ad5-nCOV candidate vaccine, state media reported, highlighting the country’s top-level asset regulator.
This is the first patent for a Covid-19 vaccine granted across China, the public newspaper People’s Daily reported on Sunday.
The document cited documents published through the State Intellectual Property Administration of China claiming the patent issued on August 11.
Saudi Arabia announced this month its goal to begin phase III clinical trials for the CanSino vaccine. CanSino said it is also in talks with Russia, Brazil and Chile to launch phase III trials in those countries.
CanSino shares in Hong Kong rose about 14% in trading Monday morning. Its Shanghai stocks were up 6.6% at noon.
Existing users, log in here
Access Hindu Businessline content on desktops, tablets, and mobile devices.
Get a diverse set of insights from our experts in portfolio, banking, economics, environment, and more.
Discover an ad-free cleaner with faster charging times.
Personalize your personal tastes and get a customized tale advice on your interest.
Existing users, login here
Larger